Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Signatures Predictive of Response to Neoadjuvant Immunotherapy in NSCLC
NCT07084610Phase 2Recruiting
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Hospital das Clínicas de Ribeirão Preto. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07084610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084610.